Literature DB >> 18839219

Severe hypertension in children and adolescents: pathophysiology and treatment.

Joseph T Flynn1, Kjell Tullus.   

Abstract

Severe, symptomatic hypertension occurs uncommonly in children, usually only in those with underlying congenital or acquired renal disease. If such hypertension has been long-standing, then rapid blood pressure reduction may be risky due to altered cerebral hemodynamics. While many drugs are available for the treatment of severe hypertension in adults, few have been studied in children. Despite the lack of scientific studies, some agents, particularly continuous intravenous infusions of nicardipine and labetalol, are preferred in many centers. These agents generally provide the ability to control the magnitude and rapidity of blood pressure reduction and should--in conjunction with careful patient monitoring--allow the safe reduction of blood pressure and the avoidance of complications. This review provides a summary of the underlying causes and pathophysiology of acute severe hypertension in childhood as well as a detailed discussion of drug treatment and the optimal clinical approach to managing children and adolescents with acute severe hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18839219     DOI: 10.1007/s00467-008-1000-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  52 in total

1.  Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies.

Authors:  C Woisetschläger; A Bur; M Vlcek; U Derhaschnig; A N Laggner; M M Hirschl
Journal:  J Hum Hypertens       Date:  2006-07-06       Impact factor: 3.012

2.  Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery.

Authors:  A V V Powroznyk; A Vuylsteke; C Naughton; S L Misso; J Holloway; A Jolin-Mellgård; R D Latimer; M Nordlander; R O Feneck
Journal:  Eur J Anaesthesiol       Date:  2003-09       Impact factor: 4.330

Review 3.  Advances in the pathogenesis and management of hypertensive crisis.

Authors:  Hiren P Patel; Mark Mitsnefes
Journal:  Curr Opin Pediatr       Date:  2005-04       Impact factor: 2.856

Review 4.  Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.

Authors:  Margareta Nordlander; Per-Ove Sjöquist; Hans Ericsson; Lars Rydén
Journal:  Cardiovasc Drug Rev       Date:  2004

Review 5.  Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma.

Authors:  Frederieke M Brouwers; Graeme Eisenhofer; Jacques W M Lenders; Karel Pacak
Journal:  Endocrinol Metab Clin North Am       Date:  2006-12       Impact factor: 4.741

Review 6.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

7.  Isradipine in the treatment of hypertensive crisis in ambulatory patients.

Authors:  M A Saragoça; J E Portela; F Plavnik; R P Ventura; L Lotaif; O L Ramos
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

8.  Vasoactive hormones in children with chronic renal failure.

Authors:  W Rauh; E Hund; G Sohl; W Rascher; O Mehls; K Schärer
Journal:  Kidney Int Suppl       Date:  1983-11       Impact factor: 10.545

9.  Stability of hydralazine hydrochloride syrup compounded from tablets.

Authors:  K S Alexander; M Pudipeddi; G A Parker
Journal:  Am J Hosp Pharm       Date:  1993-04

10.  Endothelin in the kidney in malignant phase hypertension.

Authors:  C E Whitworth; M M Veniant; J D Firth; A D Cumming; J J Mullins
Journal:  Hypertension       Date:  1995-12       Impact factor: 10.190

View more
  41 in total

1.  Anesthetic management of hypertensive crisis in a three-year-old patient with undiagnosed severe renal artery stenosis: a case report.

Authors:  Sang-Hee Park; Yoon-Sook Lee; Too Jae Min; Woon Young Kim; Jae Hwan Kim; Young Cheol Park
Journal:  Korean J Anesthesiol       Date:  2014-10-27

2.  Hypertensive emergencies in children.

Authors:  Pankaj Hari; Aditi Sinha
Journal:  Indian J Pediatr       Date:  2011-01-27       Impact factor: 1.967

3.  Correction to: "Severe hypertension in children and adolescents: pathophysiology and treatment".

Authors:  Joseph T Flynn; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2011-11-22       Impact factor: 3.714

Review 4.  Drug treatment of hypertensive crisis in children.

Authors:  Christopher A Thomas
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

5.  Clevidipine for perioperative blood pressure control in infants and children undergoing cardiac surgery for congenital heart disease.

Authors:  Joseph D Tobias; William S Schechter; Alistair Phillips; Samuel Weinstein; Robert Michler; John W Berkenbosch; Carlos Montoya
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

Review 6.  Interventions for pediatric renovascular hypertension.

Authors:  Kevin E Meyers; Anne Marie Cahill; Christine Sethna
Journal:  Curr Hypertens Rep       Date:  2014-04       Impact factor: 5.369

Review 7.  Therapy of acute hypertension in hospitalized children and adolescents.

Authors:  Tennille N Webb; Ibrahim F Shatat; Yosuke Miyashita
Journal:  Curr Hypertens Rep       Date:  2014-04       Impact factor: 5.369

8.  Hypertensive crisis in children and adolescents.

Authors:  Tomáš Seeman; Gilad Hamdani; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

9.  The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child.

Authors:  Julie Ostrye; Susan M Hailpern; Jenna Jones; Brent Egan; Katherine Chessman; Ibrahim F Shatat
Journal:  Pediatr Nephrol       Date:  2014-02-20       Impact factor: 3.714

10.  Changes in behavior as an early symptom of renovascular hypertension in children.

Authors:  Irit Krause; Roxana Cleper; Yael Kovalski; Levana Sinai; Miriam Davidovits
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.